Overview

A Study of the Long-term Safety of Sativex Use

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

Summary

Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.

Phase:

Phase 3

Details

Lead Sponsor:

GW Pharmaceuticals Ltd.

Treatments:

Nabiximols